TX-001HR

Following the FDA issuing a complete response letter, or CRL, in response to TherapeuticsMD Inc (NYSE: TXMD)'s NDA for TX-004HR, Oppenheimer downgraded the shares of the company. TX-004HR, or Yuvvexy, is the company's applicator-free vaginal estradiol soft-gel drug candidate for the treatment...